Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Sumitomo Pharma

Evaluate

Thumbnail
October 03, 2022

Myovant stands in the way of Sumitomo's consolidation

Thumbnail
November 01, 2021

US FDA approval tracker: October 2021

Article image
Vantage logo
July 09, 2021

Alzheimer’s and Covid-19 developers make hay on the stock markets

Big risers include Eli Lilly, Biogen, Moderna and Biontech.

Article image
Vantage logo
May 04, 2021

Roivant rewrites the Spac script, again

After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.

Article image
Vantage logo
January 06, 2021

US FDA approval tracker: December 2020

Article image
Vantage logo
December 21, 2020

US regulator brings year-end joy for some

Article image
Vantage logo
November 27, 2020

Go or no go? The year ends with Covid-19 vaccine approvals in sight

December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.

Article image
Vantage logo
November 25, 2020

Bergenbio dream lives on, despite Genmab's broken Axl

Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.

Article image
Vantage logo
November 20, 2020

No news is bad news for Poxel, as Metavant exits

Article image
Vantage logo
November 13, 2020

Sumitomo takes out Urovant, and Myovant beckons

With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.

Article image
Vantage logo
July 06, 2020

Obseva shows why red flags are worth heeding

A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up